Arcadia Biosciences develops agronomic performance and nutrition trait technologies aimed at improving environmental outcomes and human health. Its trait portfolio includes Nitrogen Use Efficiency, Water Use Efficiency, Salt Tolerance, Heat Tolerance, and Herbicide Tolerance; it also markets SONOVA® 400 GLA safflower oil. The company has granted more than 70 technology licenses worldwide and reports licensee progress across multiple crops. Arcadia is pursuing regulatory submissions based on Nitrogen Use Efficiency data and notes regulatory field trials for stress-tolerant soybeans (via Verdeca LLC, its joint venture with Bioceres) completed in Argentina and the US, with a first submission anticipated in 2014. Proceeds from the Series D will be used to accelerate development and commercial launch of products and to generate key data for commercial regulatory approvals. The company is based in Davis, California. Arcadia Biosciences develops agricultural technologies and health-oriented grain products, including agronomic traits such as nutrient use efficiency, water efficiency, salt tolerance, heat tolerance, and herbicide tolerance. The company is advancing a research program to identify genetic variants that naturally reduce the most harmful components of gluten in cereal grains. Arcadia’s internal research team will collaborate with Dr. Karol Sestak at Tulane University on the current project. The work builds on a prior NIH award conducted with Dr. Diter von Wettstein at Washington State University. The company says its goal is to create wholesome reduced-gluten grains to expand food choices for people with gluten intolerance and celiac disease. Arcadia is based in Davis, Calif. Arcadia Biosciences is a Davis, CA-based agricultural technology company developing technologies and products intended to benefit the environment and human health. The company is working on wheat varieties with reduced celiac disease–causing proteins and applied TILLING® high-throughput genetic screening in Phase I to identify low-toxic-protein plants. Arcadia received a two-year, $855,500 STTR Phase II grant funded by the NIDDK and the ARRA to support Phase II development in partnership with Washington State University. Phase II will take a broader approach to remove a larger number of toxic proteins while maintaining proteins critical for bread-making. Arcadia believes removing targeted toxic proteins could increase beneficial proteins and potentially yield more nutritious bread. The company operates additional facilities in Seattle and Phoenix and expects to complete Phase II research in mid-2011; no commercialization timeline has been released. Arcadia Biosciences is a Davis, Calif.–based company that engineers crops for agricultural efficiency and human-health qualities. Its first commercial product is GLA Safflower Oil, modified for high gamma-linolenic-acid (GLA) content to make foods containing it more hearty and healthy. Arcadia plans to launch the GLA Safflower Oil by the end of the year in partnership with Bioriginal Food and Science. The company has previously developed infused canola oil and rice and has engineered corn and wheat plants that require less nitrogen fertilizer to thrive. Financially, Arcadia raised $15 million in a recent second round led by Exeter Life Sciences and had previously raised $30 million. An additional $10 million is noted in connection with its 2005 purchase of agricultural firm Anawah.

Total raised

$51M

Funding rounds

4

Latest round

Series D

Latest activity

May 2014